State Street Corp Adverum Biotechnologies, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $72,450 - $112,539	48,300 Added 17.14%	330,154 $495,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $1.2 Million - $1.98 Million	-1,475,641 Reduced 83.96%	281,854 $338,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $102,600 - $162,659	-83,415 Reduced 4.53%	1,757,495 $2.3 Million
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $359,673 - $496,101	-206,709 Reduced 10.1%	1,840,910 $3.24 Million
Q3 2021 Nov 15, 2021	SELL	$2.08 - $3.6 $15.7 Million - $27.1 Million	-7,526,623 Reduced 78.61%	2,047,619 $4.44 Million
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $14.4 Million - $45.4 Million	4,300,592 Added 81.55%	9,574,242 $33.5 Million
Q1 2021 May 17, 2021	BUY	$9.26 - $14.36 $9.34 Million - $14.5 Million	1,009,060 Added 23.66%	5,273,650 $52 Million
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $13.4 Million - $19.4 Million	-1,362,799 Reduced 24.22%	4,264,590 $46.2 Million
Q3 2020 Nov 10, 2020	BUY	$10.3 - $21.64 $22.2 Million - $46.6 Million	2,152,273 Added 61.93%	5,627,389 $58 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $1.13 Million - $3.41 Million	133,027 Added 3.98%	3,475,116 $72.6 Million
Q1 2020 May 11, 2020	BUY	$7.98 - $16.32 $26.7 Million - $54.5 Million	3,342,089 New	3,342,089 $32.7 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.